ASC 350 specifies the presentation requirements for goodwill and other intangible assets, both those with finite lives and those with indefinite lives. This chapter examines the financial statement presentation and disclosures of ASC 350 through a fictitious company, PRV Corp.
U.S. GAAP permits but does not require each class of intangible assets to be separately stated in the statement of financial position; it is adequate for all the intangible assets to be aggregated and presented as a single line item.1 In contrast, SEC registrants must separately state each class of intangible assets that exceeds 5 percent of the total assets, along with the basis of determining the respective amounts, and disclose any significant addition or deletion.2
Under U.S. GAAP, the amortization expense and impairment losses3 for intangible assets must be presented in income statement line items within continuing operations unless the asset is part of a discontinued operation.4
U.S. GAAP requires that the aggregate amount of goodwill be presented as a separate line item in the statement of financial position and the aggregate amount of goodwill impairment losses be presented as a separate line item in the income statement before the subtotal income from continuing operations (or similar caption).6
If the goodwill impairment is the result of a discontinued operation, the impairment loss is contained within the section on discontinued operations.7
ASC 350 specifies the disclosure requirements for goodwill and other intangible assets, both those with finite lives and those with indefinite lives.
ASC 350-30-50-1 contains disclosure requirements for the period of acquisition of intangible assets (other than goodwill) by way of a business combination, acquisition by a not-for-profit entity, or asset acquisition. The required disclosures in the acquisition period for these assets are as follows:8
ASC 350-30-50-2 requires disclosures for every period in which an entity presents financial statements. The required disclosures are as follows:
For PRV Corp. the current period is the acquisition period, so ASC 350-30-50-1 applies. An illustrative application of the required disclosures for PRV Corp. is shown in Exhibit 5.3.
EXHIBIT 5.3 Required Disclosures for Intangible Assets in Acquirer Company's Financial Statements PRV Company
20X5 | Additions | 20X4 | |
Intangibles Subject to Amortization | |||
Customer List | $ 800,000 | $ 800,000 | $0 |
Total | 800,000 | 800,000 | 0 |
Intangibles Not Subject to Amortization | |||
Goodwill | 560,000 | 560,000 | 0 |
Total | |||
560,000 | 560,000 | 0 | |
Grand Total | $1,360,000 | $1,360,000 | 0 |
Our Company acquired the intangible asset, a proprietary customer list, from SB Co. this fiscal year. The intangible asset does not have a residual value. The intangible asset is assigned to the North America division. The weighted-average amortization period is five years. No research and development was acquired with the purchase of SB Co. |
The information in Exhibit 5.3 appears only in the period in which PRV Corp. purchases the intangible asset from SB Co. Exhibit 5.4 shows the required disclosures if this was not in the period of purchase. In that case, ASC 350-20-50-2 applies. PRV Corp. covers requirements a(1) and b of the above list of nonacquisition year disclosures in Exhibit 5.4. The written information below the matrix covers requirements a(2), and a(3). Therefore, PRV Corp. covers the requirements in parts a and b. Requirements c and d relate to intangible assets that have been renewed or extended; such intangibles are not present in this example.
EXHIBIT 5.4 Required Disclosures for Intangible Assets and Goodwill in PRV Corp.'s Financial Statements PRV Company
20X5 | 20X4 | ||||||||||
Gross | Accumulated Amortization | Net | Gross | Accumulated Amortization | Net | ||||||
Intangibles Subject to Amortization | |||||||||||
Customer List | $ 800,000 | $160,000 | $ 640,000 | $0 | $0 | $0 | |||||
Total | 800,000 | 160,000 | 640,000 | 0 | 0 | 0 | |||||
Intangibles Not Subject to Amortization | |||||||||||
Goodwill | 560,000 | 0 | 560,000 | 0 | 0 | 0 | |||||
Total | 560,000 | 0 | 560,000 | 0 | 0 | 0 | |||||
Grand Total | $1,360,000 | $160,000 | $1,200,000 | 0 | 0 | 0 | |||||
Amortization expense (not including impairment provisions) for intangible assets for the years ended December 31, 20X5, and 20X4 is $160,000 and $0, respectively. Future amortization expense for the net carrying amount of intangible assets at December 31, 20X5, is estimated to be $160,000 in fiscal 20X6, $160,000 in fiscal 20X7, $160,000 in fiscal 20X8, $160,000 in fiscal 20X9, $160,000, and $0 beyond 20X9. The aggregate amount of goodwill acquired was $560,000. All the value of the goodwill and the intangible asset was assigned to the North America division. |
An entity must disclose the following information for each recognized impairment loss related to an intangible asset in the notes to any financial statements that include the period in which the impairment loss is recognized:9
Because an entity must use fair value techniques to determine an impairment loss, it must comply with the disclosure requirements under ASC 820-10-50 regarding fair value measurements. However, it is exempt from one of the disclosure requirements under ASC 820-10-50. Specifically, if it used significant Level 3 inputs in its fair value calculations concerning intangible assets, it need not make the quantitative disclosures required by ASC 820-10-50-2(bbb).10
If an intangible asset is subject to renewal or extension, an entity must disclose information that enables financial statement users to assess the extent to which the expected future cash flows associated with the asset are affected by the entity's intent and/or ability to renew or extend the arrangement.11
A change in the estimated useful life of an intangible asset or in its expected likelihood of renewal or extension must be disclosed under ASC 275-10-50 if certain conditions are met. Generally, ASC 275-10-50 requires disclosure if it is reasonably possible on the date of the financial statements that an estimate used in the financial statements will change in the near term (i.e., within the next year) and the potential effect from the change in condition will be material to the financial statements. In other words, disclosure is appropriate if a potential change in estimate meets the reasonably possible test and the materiality test. The term reasonably possible, which is defined in the ASC Glossary, means that the chance of a future event occurring is more than remote but less than likely.12 The materiality test is met if a reasonably possible change in an estimate would have a material effect on the financial statements, even if the estimate as reported in the financial statements does not have a material effect on the financial statements.13 The materiality test is met for an estimate of the useful life of an intangible asset if either a change in the intangible's useful life or in the expected likelihood of renewal or extension of that life would be material to the financial statements. This test is applied both at the individual intangible asset level and in the aggregate to each major intangible asset class.14
For industries such as the pharmaceutical and life sciences industries that have a lot of R&D, the SEC Staff frequently asks registrants to provide more detailed disclosures in the Management Discussion and Analysis (MD&A) about their R&D activities. Specifically, the SEC Staff focuses on the status of major R&D projects and the costs incurred to date as well as the estimated completion dates, completion costs, and capital requirements.
For example, of all the SEC comment letters sent to companies in the pharmaceutical and life sciences industry, about 25 percent related to MD&A. Of these comments on MD&A, 44 percent related to the discussion of research and development expense in MD&A, and another 11 percent related to discussion of patents. The SEC Staff requests that a registrant that does not track R&D costs by project disclose that fact along with an explanation of why it does not track R&D costs by project. The SEC Staff also requests other quantitative and qualitative disclosures that describe the amount of the registrant's resources being used on each project or group of projects (e.g., by therapeutic classes). If registrants conclude they are unable to track R&D costs in any other way than by total R&D expense, they must disclose that fact. Also, if registrants cannot estimate the completion dates or costs to complete the project, the SEC Staff asks registrants to disclose the circumstances precluding such estimates.15
There is a general requirement that an acquirer disclose each major class of assets acquired and liabilities assumed in a business combination or an acquisition by a not-for-profit entity. However, there are no specific disclosure requirements in the FASB Codification related to IPR&D acquired in a business combination or acquisition by a not-for-profit entity. In contrast, when IPR&D is acquired in an asset acquisition, the acquirer must disclose the amount of such assets acquired and written off in the period, along with the line item in the income statement in which the amounts written off appear.17
An AICPA task force developed suggested language for the significant accounting policies note when IPR&D is acquired in a business combination. The following sample note disclosure is adapted from the task force's language:
IPR&D assets represent capitalized incomplete research projects that Company A acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of research projects is recorded as intangible assets on the consolidated balance sheet, rather than expensed, regardless of whether these assets have an alternative future use.18
Lastly, the AICPA task force developed the following sample language for a note specifically about the asset acquisition referenced in the significant accounting policies note:
On Oct. 5, 2009, Company A acquired a library of molecules for high-throughput screening of drug candidates and certain potential drug candidates for $300 million in cash. We allocated the consideration paid based on the relative fair value, and $100 million was attributable to the intellectual property related to the library of molecules that had an alternative future use and, as a result, was recognized as an identifiable intangible asset with an estimated remaining useful life of five years. The remaining $200 million was recorded as R&D expense because the potential drug candidates do not have an alternative future use.20
Historically, the SEC staff has routinely requested that additional information be provided about the acquired IPR&D assets. Registrants may be asked to explain how IPR&D assets were recognized, or why no or limited IPR&D assets were recorded. The SEC Staff requests that registrants provide disclosures included in the former AICPA Technical Practice Aid: Assets Acquired in a Business Combination to Be Used in Research and Development Activities: A Focus on Software, Electronic Devices and Pharmaceutical Industries. This practice aid identified best practices related to defining, valuing, accounting for, disclosing, and auditing IPR&D assets acquired in business combinations. Although the practice aid was not authoritative GAAP, there is little guidance on the measurement and disclosure of IPR&D assets.
The practice aid included the following suggested financial statement and MD&A disclosures:
ASC 350-20-50-1 requires an entity to discuss changes in the carrying amount of goodwill during the current period through the following disclosures:
Entities that report segment information in accordance with ASC 280 must provide the above information about goodwill in total and for each reportable segment and must disclose any significant changes in the allocation of goodwill by reportable segment. If any portion of goodwill has not yet been allocated to a reporting unit at the date the financial statements are issued, that unallocated amount and the reasons for not allocating that amount must be disclosed.21
If an entity recognizes an impairment loss related to goodwill, it must disclose each loss in the notes to its financial statements in the period it recognizes the impairment loss. The disclosures required under ASC 350-20-50-2 are as follows:
Because an entity must use fair value techniques to determine an impairment loss, it must comply with the disclosure requirements under ASC 820-10-50 regarding fair value measurements. However, it is exempt from one of the disclosure requirements under ASC 820-10-50. Specifically, if it used significant Level 3 inputs in its fair value calculations concerning goodwill, it need not make the quantitative disclosures required by ASC 820-10-50-2(bbb).23
In 2006, the Association of Chartered Certified Accountants (ACCA) published a research report titled “Impairment of Assets: Measurement without Disclosure?” (Research Report No. 92). Some of the key findings in the research report are:24
As early as 2003, the SEC has requested companies to expand their MD&A to describe the methodology and assumptions or estimates used to test goodwill and other intangible assets for impairment, and to highlight the reporting units for which goodwill impairment charges were reasonably likely to occur.25
Generally, the disclosures required by U.S. GAAP and IFRS are similar. Following is a description of some of the main disclosure requirements under IFRS, particularly where they differ from U.S. GAAP.
Under IFRS, an entity is required to disclose the following for each class of intangible assets, distinguishing between internally generated intangible assets and other intangible assets:27
A class of intangible assets is a grouping of assets of a similar nature and use in an entity's operations. Examples of separate classes may include:28
These classes are disaggregated (aggregated) into smaller (larger) classes if this results in more relevant information for the users of the financial statements.29
IAS 8 requires an entity to disclose the nature and amount of a change in an accounting estimate that has a material effect in the current period or is expected to have a material effect in subsequent periods. Such disclosure may arise from changes in:30
An entity shall also disclose:31
Both U.S. GAAP and IFRS require disclosure of the following for each impairment loss recognized:
However, under IFRS, management must also disclose the related cash-generating unit, which may differ from a reportable segment. Both IFRS and U.S. GAAP require disclosure of any changes in the aggregation of assets within the cash-generating unit (reportable unit), and the reasons for changing the way that the cash-generating unit (reportable unit) is identified.
A cash-generating unit is the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.32 A reporting unit is an operating segment or one level below an operating segment (also known as a component).33
See Worksheet 5 for a sample disclosure from the Vivendi Group concerning impairment testing of goodwill and other intangible assets.
3.128.190.102